A New Jersey pharmaceutical company is facing a class-action lawsuit after recalling millions of capsules of a widely prescribed heart medication that may have posed serious health risks.
The lawsuit, filed in federal court in Newark, accuses Glenmark Pharmaceuticals Inc., USA—headquartered in Mahwah—of selling defective potassium chloride capsules that failed to dissolve properly in the body.
Glenmark issued a nationwide recall of 114 batches of the capsules on or around June 25, 2024, after the U.S. Food and Drug Administration flagged the product for failing dissolution tests.
The FDA classified the recall as Class I, its most serious category, indicating a risk of serious injury or death.
The drug is commonly used to treat hypokalemia, or low potassium levels.
Martha Brewton, an Alabama resident, is leading the lawsuit on behalf of herself and other patients in her state who purchased the medication.
She says she was notified by her pharmacy that the pills she received were part of the recall.
According to the FDA and Glenmark’s own statements, the capsules could release potassium too quickly, potentially causing dangerously high potassium levels, irregular heartbeats, and cardiac arrest—especially in patients with heart or kidney conditions.
If you or a loved one suffered losses due to ingesting this, or any defective Glenmark medication, you may be entitled to compensation. To learn more, contact the trusted personal injury attorneys at Breslin and Breslin today.
